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Abstract
Objective To determine the prognostic value of the
immunohistochemical evaluation of the multidrug resis-
tance-associated protein 2 (MRP2) expression, together
with its subcellular localization in primary fallopian tube
carcinomas (PFTCs).
Methods The immunohistochemical analysis was performed
using samples originating from 70 patients with PFTCs.
Results (1) We documented that MRP2 can be localized in
the plasma membrane (MRP2c), as well as in the nuclear
envelope (MRP2n) of the PFTC cells. (2) Patients with more
advanced stage, with progression of the disease and patients
who died, showed significantly higher expression of the
MRP2n. (3) Univariate and multivariate analyses showed that
MRP2n is an unfavorable prognostic factor in PFTCs. (4) The
analysis of the classic clinicopathological data revealed that
only the FIGO stage had prognostic value, both in the uni-
variate, as well as in multivariate analysis.
Conclusions (1) This study suggests that MRP2n is a new
disadvantageous prognostic factor in PFTCs and (2) that
expression in nuclear envelope can be associated with
lower differentiation of cancer cells and their resistance to
the cisplatin. (3) We have also confirmed independent
prognostic value of FIGO stage in PFTCs.
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Introduction
Primary fallopian tube carcinomas (PFTCs) are uncommon
tumors accounting for approximately 0.14–1.8 % of all
gynecological malignancies. The annual incidence is 3.6
per 1 million women in the US. In Lower Silesia (the region
in Poland of over 3 million inhabitants), PFTC is usually
diagnosed and histologically confirmed at the frequency of
2–4 cases per year [1]. It is worth noting that the incidence
of PFTCs appears to be increasing. Stewart et al. [2] demo-
nstrated that the rate of fallopian tube cancer increased by
0.4 % annually from 1998 to 2003. Intriguingly, the rate of
ovarian cancer decreased by 2.0 % per year [2, 3].
The similarities shared between fallopian tube carci-
noma and epithelial ovarian carcinoma prompted to
establish diagnostics criteria to distinguish fallopian tube
J. Rabczynski: Deceased.
A. Halon (&)  P. Donizy
Department of Pathomorphology and Oncological Cytology,
Wroclaw Medical University, ul. Borowska 213,
50-556 Wroclaw, Poland
e-mail: ahalon2@gmail.com
V. Materna  H. Lage
Charite´ Campus Mitte, Institute of Pathology,
Chariteplatz. 1 20/21, 10117 Berlin, Germany
R. Matkowski
Department of Oncology and Division of Surgical Oncology,
Wroclaw Medical University, pl. Hirszfelda 12,
53-413 Wroclaw, Poland
R. Matkowski
Lower Silesian Oncology Centre, pl. Hirszfelda 12,
53-413 Wroclaw, Poland
J. Rabczynski
Department of Pathomorphology, Wroclaw Medical University,
Marcinkowskiego 1, 50-368 Wroclaw, Poland
P. Surowiak
Department of Histology and Embryology, Wroclaw Medical
University, Chalubinskiego 6a, 50-356 Wroclaw, Poland
123
Arch Gynecol Obstet (2013) 287:563–570
DOI 10.1007/s00404-012-2589-7
carcinoma from other primary tumors (Hu et al. modified
by Sedlis) [4–6] which stands as: (1) the tumor arises from
the endosalpinx; (2) the histological pattern reproduces the
epithelium of tubal mucosa; (3) transition from benign to
malignant epithelium is found; (4) the ovaries are either
normal or with smaller tumor than that in the tube.
However, the newest evidence indicates that ovarian
cancers may mainly originate from the tubes: recent studies
suggest that more than 50 % of high-grade serous carci-
nomas involving the ovary likely arise from fallopian tube
epithelium [7, 8].
PFTC is associated with a very poor prognosis, espe-
cially in advanced stages of the disease [9–17]. This type of
gynecological cancer has been described in the high-risk
breast–ovarian cancer families with germ-line BRCA-1
and BRCA-2 mutations [18, 19]. Furthermore, molecular
analysis revealed that unstable phenotype with highly
scattered DNA ploidy patterns and p53 gene alterations are
strongly connected with the development of PFTC [20].
Staging of the disease in accordance to the FIGO scale and
the residual disease after initial surgery are the only, wide-
accepted and reliable prognostic factors in PFTC [12, 13, 21–
23]. The depth of tubal invasion in the cases limited to the
fallopian tube [19, 23], and the presence of lymphocytic
infiltration have been suggested to play an unfavorable
prognostic role in PFTCs. The value of other commonly used
prognostic factors did not find wider acceptance [12, 13].
They may be used as evidence to support prognosis, but none
of them are independent prognostic factors.
The main function of multidrug resistance-associated
protein 2 (MRP2) in cellular pathology is participation in
the energy-dependent efflux pumps that reduce intracellu-
lar accumulation of anticancer agents [24]. In vitro
experiments revealed that enhanced immunoreactivity of
MRP2 could confer to cancer cell lines (including ovarian
cancer) chemoresistance to platinum-containing anticancer
drugs (cisplatin and carboplatin) and non-platinum-
containing drugs, including methotrexate, vinblastine, and
camptothecin derivatives [25–27].
In our previous study [27], we have reported that MRP2,
one of the 48 human ABC-transporters, also called ABCC2
or the canalicular multiple organic anion transporter
(cMOAT), may be present in the nuclear envelope of
ovarian cancer cells and that such localization is typical for
the cisplatin-resistant cancers.
MRP2 is localized in the apical membranes of canalic-
ular cells in the liver [28], in the apical membranes of
kidney proximal tubules, in epithelial cells of gall bladder,
small intestine, colon, and lung [25]. We have also demo-
nstrated that silencing of MRP2 expression is linked to
increased sensitivity of tumor cells to cisplatin [29, 30]. We
have shown that MRP2 is expressed in the nuclear enve-
lope of stem cells in healthy human tissues [27]. This
finding suggests that expression of MRP2 in the nuclear
envelope may be typical not only for drug-resistant cells,
but also for low differentiated cells.
This study aimed at immunohistochemical examination
of the prognostic and predictive value of MRP2 expression
and its subcellular localization in patients with PFTC.
Patients and methods
Patients
Immunohistochemical examination was performed retro-
spectively on tissue samples taken for routine diagnostic
purposes. The study included all seventy patients with
PFTC (Table 1) diagnosed or consulted in the Department
of Pathomorphology, Wroclaw Medical University, Poland
in the years 1982–2002. The cases were not stratified for
known preoperative or pathological prognostic factors.
The study was approved by an Institutional Review
Board (IRB). Tissue samples and paraffin blocks collected
in our institution seem to be one of the largest collection
worldwide, and the largest in Poland.
Age of patients ranged from 38 to 84 (mean 57.5).
Histological classification of PFTC was performed
according to the WHO ovarian tumor classification and the
stage of disease was established based on the FIGO scale
for fallopian tube cancer.
Histological classification revealed: 26 endometrioid
cancers, 16 undifferentiated, 15 serous, 8 transitional, 3 clear
cell and 2 another type. Thirty-eight patients were FIGO I
stage, 14 FIGO II stage, 16 FIGO III and 2 FIGO IV
(Table 1). The mean observation time was 52 months (range
2–178). Thirty-eight patients died with recurrence of the
disease. Fourteen patients died without evidence of disease
progression. The patients were monitored by periodic med-
ical check-ups, CA-125 serum levels, ultrasonographic and
radiological examinations. Progression of the disease was
defined as clinical or biochemical recurrence of the disease.
Authors were not able to collect data concerning the
residual disease after initial surgery in the investigated group of
patients. Data concerning patients outcome, disease remission
and overall survival time were collected based on hospital
documentation and Lower Silesian Centre Registry database.
Tissue sampled from studied tumors were fixed in 10 %
buffered formalin and embedded in paraffin. In each case,
hematoxylin and eosin stained preparations were subjected
to histopathological evaluation by two pathologists.
Immunohistochemistry
Formalin-fixed paraffin embedded tissue was freshly cut
(4 lm). Immunohistochemistry was done as described
564 Arch Gynecol Obstet (2013) 287:563–570
123
previously [27, 29, 30]. For the detection of MRP2, a mono-
clonal mouse antibody (clone M2I-4; Monosan, Uden, the
Netherlands) was diluted 1:100 in the antibody diluent,
background reducing (DakoCytomation, Poland). Tested
sections were incubated with antibodies for 1 h at room
temperature. Subsequent incubations involved biotinylated
antibodies (15 min, room temperature) and streptavidin–
biotinylated peroxidase complex (15 min, room temperature)
(LSAB?, HRP, DakoCytomation, Poland). NovaRed (Vector
Laboratories, UK) was used as a chromogen (10 min, at room
temperature). All the sections were counterstained with
Meyer’s hematoxylin. In each case, control reactions were
included, in which specific antibody was substituted by the
primary mouse negative control (DakoCytomation, Poland).
Control reactions included: positive control involving
sections of human healthy liver, control reactions on tissue
microarrays (Oligene GmbH, Berlin, Germany) with healthy
human tissues, immunocytochemistry on the level of electron
microscope, RT-PCR reactions, prediction of nuclear locali-
zation signal (NLS) in ABCC2 using the software ‘‘Predict-
NLS Online’’ (Version Jun 7, 2000) (http://cubic.bioc.columbia.
edu/cgi/var/nair/resonline.pl). They were performed and
described in detail previously [27, 29, 30].
Scoring of immunostaining results
Intensity of the immunohistochemical reactions was
appraised using the semi-quantitative immunoreactive
score (IRS) scale [31], in which intensity of the reaction
and percentage of positive cells were considered (Table 2).
The final result represented a product of scores given for
individual traits and ranged between 0 and 12. Intensity of
the reactions was evaluated independently by two pathol-
ogists. In cases of divergences, the evaluation was repeated
using double-headed microscope.
Statistical analysis
Statistical analysis of the results took advantage of Statis-
tica 98 PL software (Statsoft, Poland). The employed tests
included ANOVA rank test of Kruskal–Wallis, Spearman’s
rank correlation, Kaplan–Meier’s statistics and log-rank
tests were performed using SPSS software (release 10.0;
SPSS Inc., Chicago, IL, USA) to estimate significance of
differences in survival times. We have also performed
Kaplan–Meier’s statistics and log-rank tests on subgroup of
14 patients receiving cisplatin-based chemotherapy after
the surgery. Using F Cox test, we have also performed
multivariate survival analysis. Multivariate analysis cov-
ered data concerning age, tumor grade, FIGO stage, and
MRP2 expression parameters.
Results
MRP2 immunostaining in PFTC
We documented the expression of MRP2 in the normal
ovarian epithelium in apical cell membrane of the majority of
Table 1 Patient and tumor characteristics—survival analysis of the
data (log-rank and F Cox tests)




All patients 70 (100)
























Clear cell 3 (4)
Other 2 (3)
Chemotherapy 14 (20)
a Differences in the sum to 100 % in groups are due to rounding
Bold values indicate statistically significant (Hazard Ratio is 1.0684)
Table 2 Evaluation criteria of MRP2 expression using the immu-
noreactive score (IRS) [31]
Percentage of positive cells Points Intensity of reaction Points
No positive cells 0 No reaction 0
\10 % of positive cells 1 Weak reaction 1
10–50 % of positive cells 2 Moderate reaction 2
51–80 % of positive cells 3 Intense reaction 3
[80 % of positive cells 4
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the cells and in the nuclear envelope in few cases (Fig. 1a). In
case of PFTCs, the MRP2-specific staining reactions demo-
nstrated a subcellular localization of MRP2 in the plasma
membrane and cytoplasm (MRP2c) (Fig. 1b) as well as in the
nuclear envelope (MRP2n) (Fig. 1c) and both localizations
(Fig. 1d). The localization and the expression level of MRP2
were heterogenic in individual cases. Mean expression of
MRP2c was 1.26 ± 1.77 SD (range 0–8) in the IRS scale and
in case of MRP2n mean expression was 4.37 ± 3.65 SD
(range 0–12) in the IRS scale. The expression of MRP2 in the
nuclear envelope was significantly higher compared to its
expression in the plasma membrane (P \ 0.001).
Fig. 1 Immunohistochemical localization of MRP2 expression in: a normal fallopian tube epithelium, b–d primary fallopian tube carcinomas
(hematoxylin, 9400)
Table 3 Relationships between
MRP2 expression and
clinicopathological factors
(ANOVA rank test of Kruskal–
Wallis, Spearman’s rank
correlation)
a Spearman’s rank correlation
Studied parameter MRP2 in the nuclear envelope MRP2 in the plasma membrane
Agea P = 0.8407 P = 0.5067
R = 0.02444 R = -0.0807
FIGO H (9, N = 70) = 18.14576 H (9, N = 70) = 11.51831
P = 0.0319 P = 0.3303
Grade H (9, N = 70) = 0.2527233 H (9, N = 70) = 1.140207
P = 0.8813 P = 0.5655
Histology H (9, N = 70) = 4.338052 H (9, N = 70) = 3.603356
P = 0.3622 P = 0.4624
Progression of the disease H (9, N = 70) = 7.075123 H (9, N = 70) = 0.6623821
P = 0.0078 P = 0.6841
Death of the patient H (9, N = 70) = 29.39694 H (9, N = 70) = 0.1655955
P = 0.00001 P = 0.5993
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Relationships between expression of MRP2
and clinicopathological data
Patients with more advanced stage, and patients who died,
showed significantly higher expression of the MRP2n
(Table 3).
Clinicopathological data and patients survival
The analysis of the classic clinicopathological data
revealed that only the FIGO stage had prognostic value,
both in the univariate, as well as in multivariate analysis
(Table 1).
MRP2 expression and patient survival
Using the log-rank test and the Kaplan–Meier’s analysis,
we revealed that the MRP2c expression has no prognostic
value (Fig. 2a). In the case of the MRP2n, we observed
shorter overall survival time in group of patients with
higher expression of the MRP2n (IRS 3–12) compared to
the group with lower expression of the MRP2n (IRS 0–2)
(Fig. 2b).
Similarly, the analysis of the data obtained from 14
patients subjected to postoperative cisplatin-based chemo-
therapy revealed that the MRP2c (Fig. 2c) had no prog-
nostic value, but patients with tumors showing higher
expression of the MRP2n (IRS 3–12) had significantly
shorter overall survival time comparing with the patient
group with lower expression of the MRP2n (IRS 0–2)
(Fig. 2d). Patients with expression of the MRP2n IRS 0–2
(n = 6) survived the entire observation period.
Multivariate analysis confirmed the lack of prognostic
value of the MRP2c (P = 0.7665) and the significant role
of the MRP2n (P = 0.0115).
Discussion
In this analysis, we investigated two aspects: the significance
of the MRP2 expression localized in the nuclear enve-
lope (parameter described earlier [27] as disadvantageous
Fig. 2 Kaplan–Meier curves
for survival and expression of
MRP2. a Cytoplasmic MRP2
expression and patients survival
(entire studied group), b nuclear
envelope MRP2 expression and
patients survival (entire studied
group), c cytoplasmic MRP2
expression and patients survival
(chemotherapy-treated
subgroup), d nuclear envelope
MRP2 expression and patients
survival (chemotherapy-treated
subgroup)
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prognostic and predictive factor during cisplatin therapy of
the ovarian cancer) and the prognostic and predictive value
of MRP2 expression in PFTCs. To the best of our knowl-
edge, this is the first analysis of the MRP2 immunoreactivity
in clinical specimens of PFTCs.
PFTC is relatively rare and is associated with poor
prognosis [9–11]. From the various prognostic factors
only the staging of the disease at the time of diagnosis in
accordance with the FIGO classification has an estab-
lished value [13, 21]. In this work, using univariate and
multivariate analysis, we confirmed the significant prog-
nostic value of the FIGO scale in the PFTCs. Simulta-
neously, we have not observed the prognostic value of
the other clinicopathological parameters such as age,
grade, and histological type. It is hard to establish the
prognostic criteria for PFTC due to limited size of the
group with the primary tubal cancer and specific histol-
ogy of tumors. Primary fallopian tube malignant epithe-
lial tumors do not reveal any specific histological
structure. They are derived from Mu¨llerian duct epithe-
lium and indirectly from epithelium overlying the
celoma. Thus, these neoplasms in their histology reflect
the whole range of epithelial tumors commonly found in
female genital tract beginning from uterine cervix fin-
ishing at ovaries [9].
Our results revealed that MRP2 can be localized both, in
the plasma membrane, as well as in the nuclear envelope
both in the normal ovarian epithelium and in the case of the
PFTC. Considering our previous study [27] and data
described here, we suggest that expression of the MRP2 in
nuclear envelope in normal ovarian epithelium is charac-
teristic for the stem cells of the epithelium. In the case of
the PFTC cancer cells we have shown, similarly as in the
case of the ovarian cancer [27], that expression of the
MRP2 in the cytoplasmic membrane has no prognostic
value, but its expression in the nuclear envelope can serve
as an independent prognostic factor. In this work we doc-
umented for the first time that MRP2n is an independent
unfavorable prognostic factor of the PFTC. We acknowl-
edge the limitation of our study with its population size.
However the study included all cases of fallopian tube
cancer diagnosed or consulted in our Department in the
years 1982–2002. In few older blocks (6 blocks from years
1992–1998), the evaluation of MRP2 intensity was more
difficult but readable.
In above-mentioned studies, we also observed that in the
group of the patients subjected to postoperative cisplatin-
based chemotherapy, the high expression of MRP2n was
the disadvantageous prognostic factor. In this group, 100 %
of the patients with low (IRS 0–2) expression of the
MRP2n survived the entire observation period. Unfortu-
nately, in studied group only 14 patients were treated with
chemotherapy after surgery, thus to determine the
prediction value of the MRP2n expression in PFTC, the
investigations of the bigger group of the patients is crucial.
Prognostic significance of the MRP2 expression was also
widely discussed in other malignancies, such as esophageal
squamous cell carcinoma [32], medullary thyroid carcinoma
[33], pancreatic cancer [34], squamous cell carcinoma of the
head and neck [35], lung cancer [36, 37], hepatocellular [38]
and cholangiocellular carcinoma [39]. Although MRP2 con-
fers the chemoresistance in several cancer types, its implica-
tion on gynecological neoplasms is still unclear [40–45].
MRP2 has been found to be overexpressed in several types of
cisplatin-resistant cell lines [25] as a potential factor involved
in ATP-dependent active efflux of the wide range of struc-
turally unrelated cytotoxic agents. However, Ohishi et al. [42]
demonstrated that the MRP2 mRNA level in serous papillary
adenocarcinoma of the ovary was not associated with clinical
outcome after platinum-based chemotherapy. Materna et al.
[43] revealed a distinct tendency in correlation between high
MRP2 mRNA expression and poor prognosis in ovarian
carcinoma patients, but due to the low case number, the dif-
ference was statistically not significant. Immunohistochemi-
cal evaluation of the MRP2 expression was performed on 24
specimens of ovarian carcinoma, but this study also demon-
strated no correlation with clinical response to platinum-based
chemotherapy [44]. Interestingly, Ma et al. [45] using short
hairpin RNA (shRNA) observed that the knock down of
MRP2 effected in an increased intracellular cisplatin accu-
mulation. Taking into account previous contradictory data,
further studies are needed to fully determine the role of MRP2
in ovarian cancer progression.
In summary, in this work we have shown that MRP2 is
localized in the nuclear envelope of the PFTC cells. This
localization can be attributed to the lower differentiation of
the cancer cells and their resistance to the cisplatin. We
have also confirmed the significant prognostic value of the
FIGO scale in PFTC.
This study supports the concept of MRP2 expression in
nuclear envelope as possible marker of poor prognosis and
resistance to cisplatin-based chemotherapy in PFTC patients
but does not confirm its cytoplasmic expression value in
those aspects. Estimation of MRP2n expression may provide
valuable prognostic and predictive information proving that
IHC may be a simple and accessible tool in identifying
patients with worse prognosis and possible chemoresistance
to cisplatin. Taking into account previous contradictory data
and limitation of our study, further investigations are needed
to fully determine the role of MRP2 in PFTC progression,
prognosis and chemoresistance.
Acknowledgments The study was supported by research fellowship
within ‘‘Development program of Wroclaw Medical University’’
funded from European Social Fund, Human Capital, National Cohe-
sion Strategy (contract no. UDA-POKL.04.01.01-00-010/08-00) and
Grant no. 1200 of Wroclaw Medical University.
568 Arch Gynecol Obstet (2013) 287:563–570
123
Conflict of interest None to declare.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Reports based on data of the National Cancer Registry in Poland:
http://85.128.14.124/krn/english/index.asp
2. Stewart SL, Wike JM, Foster SL, Michaud F (2007) The inci-
dence of primary fallopian tube cancer in the United States.
Gynecol Oncol 107:392–397
3. Wethington SL, Herzog TJ, Seshan VE et al (2008) Improved
survival for fallopian tube cancer: a comparison of clinical
characteristics and outcome for primary fallopian tube and
ovarian cancer. Cancer 113:3298–3306
4. Hu CY, Taymour ML, Hertig AT (1950) Primary carcinoma of
the fallopian tube. Am J Obstet Gynaecol 59:58–67
5. Sedlis A (1978) Carcinoma of the fallopian tube. Surg Clin North
Am 58:121–129
6. Ng P, Lawton F (1998) Fallopian tube carcinoma–a review. Ann
Acad Med Singapore 27:693–697
7. Karst AM, Levanon K, Drapkin R (2011) Modeling high-grade
serous ovarian carcinogenesis from the fallopian tube. Proc Natl
Acad Sci USA 108:7547–7552
8. Levanon K, Crum C, Drapkin R (2008) New insights into the
pathogenesis of serous ovarian cancer and its clinical impact.
J Clin Oncol 26:5284–5293
9. Alvarado-Cabrero I, Young RH, Vamvakas EC et al (1999)
Carcinoma of the fallopian tube: a clinicopathological study of
105 cases with observations on staging and prognostic factors.
Gynecol Oncol 72:367–379
10. Baekelandt M, Nesbakken AJ, Kristensen GB et al (2000) Car-
cinoma of the fallopian tube. Clinicopathologic study of 151
patients treated at the Norwegian Radium Hospital. Cancer
89:2076–2084
11. Nordin AJ (1994) Primary carcinoma of the fallopian tube: a
20-year literature review. Obstet Gynaecol Surv 49:349–361
12. Hellstro¨m AC, Silfverswa¨rd C, Nilsson B et al (1994) Carcinoma
of the fallopian tube. A clinical and histopathologic review. The
Radiumhemmet series. Int J Gynecol Cancer 4:395–400
13. Rosen AC, Ausch M, Hafner E et al (1998) A 15-year overview
of management and prognosis in fallopian tube carcinoma.
Austrian Cooperative Study Group for Fallopian Tube Carci-
noma. Eur J Cancer 34:1725–1729
14. Rabczyn´ski J, Zio´łkowski P, Kochman A et al (1998) Primary
fallopian tube carcinoma. Histopathology of 46 cases. Pol J
Pathol 49:285–292
15. Papadimitriou CA, Markaki S, Lianos E et al (2009) Clinico-
pathological features of primary fallopian tube carcinoma: a
single institution experience. Eur J Gynaecol Oncol 30:389–395
16. Pectasides D, Pectasides E, Papaxoinis G et al (2009) Primary
fallopian tube carcinoma: results of a retrospective analysis of 64
patients. Gynecol Oncol 115:97–101
17. Liapis A, Bakalianou K, Mpotsa E et al (2008) Fallopian tube
malignancies: a retrospective clinical pathological study of 17
cases. J Obstet Gynaecol 28:93–95
18. Rose PG, Shrigley R, Wiesner GL (2000) Germline BRCA2
mutation in patient with primary fallopian tube carcinoma: a case
report. Gynecol Oncol 77:319–320
19. Aziz S, Kuperstein G, Rosen B et al (2001) A genetic epidemi-
ological study of carcinoma of the fallopian tube. Gynecol Oncol
80:341–345
20. Pectasides D, Pectasides E, Economopoulos T (2006) Fallopian
tube carcinoma: a review. Oncologist 11:902–912
21. Kosary C, Trimble EL (2002) Treatment and survival for women
with fallopian tube carcinoma: a population-based study. Gynecol
Oncol 86:190–191
22. Gadducci A, Landoni F, Sartori E et al (2001) Analysis of
treatment failures and survival of patients with fallopian tube
carcinoma: a cooperation task force (CTF) study. Gynecol Oncol
81:150–159
23. Peters WA, Andersen WA, Hopkins MP (1988) Prognostic fea-
tures of carcinoma of the fallopian tube. Obstet Gynecol
71:757–762
24. Kruh GD, Belinsky MG (2003) The MRP family of drug efflux
pumps. Oncogene 22:7537–7552
25. Taniguchi K, Wada M, Kohno K et al (1996) A human canalic-
ular multispecific organic anion transporter (cMOAT) gene is
overexpressed in cisplatin-resistant human cancer cell lines with
decreased drug accumulation. Cancer Res 56:4124–4129
26. Liedert B, Materna V, Schadendorf D et al (2003) Overexpres-
sion of cMOAT (MRP2/ABCC2) is associated with decreased
formation of platinum-DNA adducts and decreased G2-arrest in
melanoma cells resistant to cisplatin. J Invest Dermatol 121:
172–176
27. Surowiak P, Materna V, Kaplenko I et al (2006) ABCC2 (MRP2,
cMOAT) can be localized in the nuclear membrane of ovarian
carcinomas and correlates with resistance to cisplatin and clinical
outcome. Clin Cancer Res 12:7149–7158
28. Wada M, Toh S, Taniguchi K et al (1998) Mutations in the
canalicular multispecific organic anion transporter (cMOAT)
gene, a novel ABC transporter, in patients with hyperbilirubine-
mia II/Dubin-Johnson syndrome. Hum Mol Genet 7:203–207
29. Materna V, Stege A, Surowiak P et al (2006) RNA interference-
triggered reversal of ABCC2-dependent cisplatin resistance in
human cancer cells. Biochem Biophys Res Commun 348:153–
157
30. Kowalski P, Surowiak P, Lage H (2005) Reversal of drug-resis-
tant phenotypes by an autocatalytic multitarget multiribozyme
directed against the transcripts of the ABC transporters MDR1/P-
gp, MRP2, and BCRP. Mol Ther 11:1393–1398
31. Remmele W, Stegner HE (1987) Recommendation for uniform
definition of an immunoreactive score (IRS) for immunohisto-
chemical estrogen receptor detection (ER-ICA) in breast cancer
tissue. Pathologe 8:138–140
32. Yamasaki M, Makino T, Masuzawa T et al (2011) Role of
multidrug resistance protein 2 (MRP2) in chemoresistance and
clinical outcome in oesophageal squamous cell carcinoma. Br J
Cancer 104:707–713
33. Ruggeri RM, Sciacchitano S, Vitarelli E et al (2006) Immuno-
expression of multidrug-resistance protein 2 and cyclooxygenase
2 in medullary thyroid carcinomas. Arch Pathol Lab Med
130:1014–1019
34. Noma B, Sasaki T, Fujimoto Y et al (2008) Expression of mul-
tidrug resistance-associated protein 2 is involved in chemother-
apy resistance in human pancreatic cancer. Int J Oncol
33:1187–1194
35. van den Broek GB, Wildeman M, Rasch CR et al (2009)
Molecular markers predict outcome in squamous cell carcinoma
of the head and neck after concomitant cisplatin-based chemo-
radiation. Int J Cancer 124:2643–2650
36. Kim YH, Ishii G, Goto K et al (2009) Expression of breast cancer
resistance protein is associated with a poor clinical outcome in
patients with small-cell lung cancer. Lung Cancer 65:105–111
Arch Gynecol Obstet (2013) 287:563–570 569
123
37. Ushijima R, Takayama K, Izumi M et al (2007) Immunohisto-
chemical expression of MRP2 and clinical resistance to platinum-
based chemotherapy in small cell lung cancer. Anticancer Res
27:4351–4358
38. Korita PV, Wakai T, Shirai Y et al (2010) Multidrug resistance-
associated protein 2 determines the efficacy of cisplatin in
patients with hepatocellular carcinoma. Oncol Rep 23:965–972
39. Rau S, Autschbach F, Riedel HD et al (2008) Expression of the
multidrug resistance proteins MRP2 and MRP3 in human cho-
langiocellular carcinomas. Eur J Clin Invest 38:134–142
40. Sandusky GE, Mintze KS, Pratt SE et al (2002) Expression of
multidrug resistance-associated protein 2 (MRP2) in normal
human tissues and carcinomas using tissue microarrays. Histo-
pathology 41:65–74
41. Chen H, Hao J, Wang L (2009) Coexpression of invasive markers
(uPA, CD44) and multiple drug-resistance proteins (MDRI,
MRP2) is correlated with epithelial ovarian cancer progression.
Br J Cancer 101:432–440
42. Ohishi Y, Oda Y, Uchiumi T et al (2002) ATP-binding cassette
superfamily transporter gene expression in human primary
ovarian carcinoma. Clin Cancer Res 8:3767–3775
43. Materna V, Pleger J, Hoffmann U et al (2004) RNA expression of
MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in
ovarian carcinoma patients: correlation with chemotherapeutic
response. Gynecol Oncol 94:152–160
44. Guminski AD, Balleine RL, Chiew YE et al (2006) MRP2
(ABCC2) and cisplatin sensitivity in hepatocytes and human
ovarian carcinoma. Gynecol Oncol 100:239–246
45. Ma JJ, Chen BL, Xin XY (2009) Inhibition of multi-drug resis-
tance of ovarian carcinoma by small interfering RNA targeting to
MRP2 gene. Arch Gynecol Obstet 279:149–157
570 Arch Gynecol Obstet (2013) 287:563–570
123
